MedTrace Logo

A Multiple Ascending Dose Study of LW402 in Healthy Volunteers

NCT07546149 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-04-22

No results posted yet for this study

Summary

This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety, tolerability and pharmacokinetics of multiple doses of LW402 tablets in healthy volunteers.

Conditions

  • Safety Evaluation of Escalating Doses

Interventions

DRUG

Experimental

LW402 Tablets

DRUG

Placebo

LW402 Placebo Tablets

Sponsors & Collaborators

  • Shanghai Longwood Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wei Zhao · Shandong First Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-15
Primary Completion
2025-12-09
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07546149 on ClinicalTrials.gov